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Abstract
Background: The inherent glycosidase inhibitory activity and potentially therapeutic value of the
polyhydroxylated pyrrolizidine alkaloids containing a hydroxymethyl substituent at the C-3 position have
been well documented. Belonging to this class, the naturally occurring hyacinthacine C-type alkaloids are of
general interest among iminosugar researchers. Their selective micromolar α -glycosidase inhibitory ranges
(10 - 100 μM) suggest that these azasugars are potential leads for treating type II diabetes. However, the
structures of hyacinthacine C1, C3 and C4 are insecure with hyacinthacine C5 being recently corrected.
Objective: This review presents the hyacinthacine C-type alkaloids: their first discovery to the most recent
advancements on the structures, biological activities and total synthesis. Conclusion: The hyacinthacine C-
type alkaloids are of exponentially increasing interest and will undoubtedly continue to be reported as
synthetic targets. They represent a challenging but rewarding synthetic feat for the community of those
interested in accessing biologically active iminosugars. Since 2009, ten total syntheses have been employed
towards accessing similarly related products but only three have assessed the glycosidase inhibitory activity of
the final products. This suggests the need for an accessible and universal glycosidase inhibitory assay so to
accurately determine the structure-activity relationship of how the hyacinthacine C-type alkaloids inhibit
specific glycosidases. Confirming the correct structures of the hyacinthacine C-type alkaloids as well as
accessing various analogues continues to strengthen the foundation towards a marketable treatment for type
II diabetes and other glycosidase related illnesses.
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Abstract: This review presents the hyacinthacine C-type alkaloids: their first discovery through to the most recent 
advancements on the structures, biological activities and total synthesis.  
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1. PYRROLIZIDINE ALKALOIDS 
Pyrrolizidine alkaloids, particularly those that contain a 
hydroxymethyl substituent at C-1 (figure 1), have been of 
exponentially growing interest since the 1960s.[1]  
 
Figure 1. General structure for pyrrolizidine alkaloids. 
 
Their appreciation is largely a result of the increasing 
number of deaths to livestock that have consumed plants rich 
in pyrrolizidine alkaloids.[1] A memorable example occurred 
in Australia in the late 1970s, whereby a large number of 
chicken poisonings were reported.[2] On closer inspection, 
researchers found that the ill-thrift, ascites and degenerative 
lesions on the chickens, were the result of a commercial 
poultry feed containing heliotrine and lasiocarpine (Figure 
2): pyrrolizidine alkaloids found in the seeds of 
Heliotropium stenophyllum.[2] However, it is more alarming 
that many cases of liver disease and cancer in humans have 
been the direct result of pyrrolizidine alkaloid 
consumption.[3-6] This wide spread occurrence is not 
surprising since there have been recorded findings of 
pyrrolizidine alkaloids detected in wheat flour, honey and 
also cow’s milk.[7-9] At least from an economic point of 
view, it remains important that improved methods of 
detection, chromatographic separation and chiefly, natural 
product characterization are continually explored. In the 
early 1980s, pyrrolizidine alkaloids were deemed pernicious 
upon ingestion and were consequently flagged as a world-
wide health concern.[1] Their toxicity is a result of the 1,2-
unsaturated bond, in combination with an ester at the C-9 
position.[1] After consumption, hepatic mixed function 
oxidases convert these pyrrolizidine alkaloids to their 
counter pyrrole derivatives. These metabolic products are 
highly reactive and can scar various organs in the body, 
particularly rich in thiol containing amino acids.[10, 11] 
 
 
Figure 2. Pyrrolizidine alkaloids heliotrine and lasiocarpine. 
 
During this time, only a few examples existed of 
pyrrolizidine alkaloids that displayed anti-tumor[12] and 
neuromuscular blocking[13] activities and so this class of 
alkaloid was generally thought to be toxic. However, by the 
late 1980s, this view drastically changed after the discovery 
of the polyhydroxylated pyrrolizidine alkaloids containing a 
hydroxymethyl substituent at the C-3 position.[14] Alexine 
(Figure 3) was the first compound of this type to be isolated 
from natural sources, more specifically, the legume Alexia 
leiopetala.[14] Its structure was unequivocally confirmed by 
X-ray crystallography[14] and just a few months later, its C-
7a epimer (also crystalline), australine, was reported as a 
constituent of Castanospermum australe seeds (Figure 
3).[15] Following these discoveries, a number of closely 
related epimers were also isolated from C. australe.[16-19] 
Interestingly, alexine and australine along with their related 
epimers displayed notable anti-viral properties as well as low 
IC50 values towards specific glycosidases.[14, 15] These 
findings attracted significant attention to the 
polyhydroxylated pyrrolizidine alkaloids, as contrary to their 
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Figure 3. Polyhydroxylated pyrrolizidine alkaloids 
containing a hydroxymethyl substituent at C-3, alexine and 
its C-7a epimer australine. 
 
The polyhydroxylated pyrrolizidine alkaloids unique 
structure and high oxidation level gives rise to their reported 
anti-viral properties and other medicinal applications such as 
treatment for diabetes, obesity and cancer.[20, 21] Their 
affinity for glycosidases is a result of their mimicry of 
pyranosyl and furanosyl moieties of carbohydrates. The 
strength and specific inhibition is largely dependent on the 
shape, size and stereoconfiguration as well as the target 
glycosidase. Before the discovery of alexine and australine, 
it was generally accepted that glycosidase inhibitors were 
restricted in Nature and so the search for related analogues 
became of increasing interest for medicinal chemists.[15], 
[22-25]  
It was therefore an exciting discovery when the first 
pentahydroxylated pyrrolizidine alkaloid, casuarine, was 
isolated from the bark of Casuarina equisetifolia L (Figure 
4) reported by Nash et al. in 1994.[26] Nash and colleagues 
were initially interested in the bark of C. equisetifolia L 
because of its traditional use as a medicine to treat diarrhoea, 
dysentery and colic.[26, 27] Perhaps a more convincing 
reason for Nash et al. to examine this natural source, was 
due to previous reports of prescribed C. equisetifolia L bark 
extract for the treatment of breast cancer in Western 
Samoa.[26] Their investigation started with an GC-MS 
analysis of the extract, where a pentahydroxy- nitrogen-
containing species, later established to be casuarine, was 
identified to be one of the major compounds present. 
Moreover, it contained the highest oxidation level to be 
found in any related naturally occurring iminosugar. Its 
analogous structure to alexine and australine led researchers 
to suspect it contained inherent glycosidase inhibitory 
activity. This was confirmed to be correct after various 






Figure 4. Polyhydroxylated pyrrolizidine alkaloid casuarine. 
 
Casuarine has also been identified as a common constituent 
within the leaves and seeds of Eugenia jambolana, a plant 
native to India known particularly for its various medicinal 
uses including the management of diabetes and bacterial 
infections.[28] Although initially labelled as uniflorine A 
and B, it was later corrected that casuarine along with its C-6 
epimer were the biologically active constituents isolated in 
2000 from the leaves of a similar species Eugenia uniflora 
(Figure 5).[29-35] The only other naturally occurring 
casuarine epimer reported in the literature is the C-3 epimer 
which was isolated from Myrtus communis L. in 2006 by 
Fleet et al.[36] With respect to casuarine, its notably weaker 




Figure 5. Casuarine derivatives 6-epi-casuarine and 3-epi-
casuarine. 
 
2. HYACINTHACINE ALKALOIDS 
One recently discovered subclass of polyhydroxylated 
pyrrolizidine alkaloid that has attracted considerable 
attention for their inherent glycosidase inhibitory activities 
are the hyacinthacine alkaloids. Despite their analogous 
structure to casuarine, alexine and australine, these alkaloids 
have been named after their original source, namely the 
Hyacinthaceae subfamily within the Asparagaceae.[37] 
Shown in Figure 6, the hyacinthacine alkaloids can be 
divided into three classes: Hyacinthacine A, B and C; 
whereby the letter assignment denotes whether 0, 1 or 2 
hydroxy/hydroxymethyl substituents are found on the B-ring 
of the alkaloid, respectively.  
 
Figure 6. Hyacinthacines A1, B1, C1, containing 0, 1 and 2 
hydroxy or hydroxymethyl substituents on the B-ring of the 
pyrrolizidine, respectively.  
 
The discovery of the hyacinthacine alkaloids can be traced 
back to the late 1960s and is considered an unprecedented 
finding, largely because Asparagaceae is unrelated to the 
Leguminosae, Casuarinaceae and Mytaceae plant 
families.[38] In 1967 a report from The Veterinary Record 
written by Thursby-Pelham, detailed the toxicological effects 
on livestock after consuming Hyacinthoides non-scripta.[39] 
More specifically, Thursby-Pelham found that ingestion led 
to abdominal pain and dysentery in horses and lethargy and 
dullness in cows.[39] The plants metabolites however 
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remained a mystery until 1997, where, prompted by this 
report and perhaps also the availability of this material, Fleet 
et al. identified the presence of five pyrrolidine alkaloids 
present in the ethanolic fraction of the leaves.[40] This was 
the first report of any such alkaloids from the Hyacinthaceae 
species and although the plant was considered detrimental to 
livestock health, Fleet et al. were able to demonstrate that the 
isolated pyrrolidine alkaloids were potential therapeutic 
leads. Glycosidase inhibition studies of these isolates found 
that they might serve as useful chemotherapeutic agents 
against cancers, viruses and also diabetes.[38]  
 
2.1. Hyacinthacine isolation and biological activities 
Two years after this novel finding, several of the same 
authors led by Asano, reported their investigation into the 
fruits and stalks of the H. non-scripta.[41] To further explore 
the natural abundance of similar compounds, their research 
also detailed the analysis of the bulbs of a related species, 
Scilla campanulata.[41]   
In addition to the isolation of six pyrrolidine alkaloids, three 
novel polyhydroxylated pyrrolizidine alkaloids labelled as 
hyacinthacines were reported (See Table 1).[41] More 
specifically, from the 50% ethanoic extracts of the H. scripta 
stalks, hyacinthacine C1 was isolated, and from the 50% 
ethanoic extract of the S. campanulata bulbs, hyacinthacine 
B2 was isolated.[41] Hyacinthacine B1 was common in both 
plants and thus found as a constituent in both extracts.[41] 
Although not necessarily potent, these three alkaloids gained 
considerable interest for their selective glycosidase 
inhibition. Hyacinthacine B1 and B2 both displayed weak 
inhibition of almond β-glucosidase (IC50 values of 320 µM 
and 100 µM, respectively) and bovine liver β-galactosidase 
(IC50 values of 110 µM and 160 µM, respectively). Both 
alkaloids also showed selective inhibition for rat intestinal 
lactase β-galactosidase, however hyacinthacine B2 proved far 
more active (IC50 = 3.6 µM) than hyacinthacine B1 (IC50 = 
270 µM). Interestingly, hyacinthacine C1 proved moderately 
active against the amyloglucosidase of Aspergillus niger 
(IC50 = 84 µM), whereas hyacinthacine B1 and B2 displayed 
no inhibition for these two glycosidases.  
Given these noteworthy glycosidase inhibitory activities, the 
therapeutic potential warranted further investigation of the 
hyacinthacine alkaloids. Since there had not yet been a 
proven synthetic route to access these novel structures, 
natural product investigation was the only viable option. To 
increase the chance of finding similar novel hyacinthacine 
alkaloids, the same authors reported in 2000, their 
investigation into the bulbs of the related Muscari 
armeniacum whereby they identified four novel 
hyacinthacine type alkaloids.[42] More specifically, Asano 
and co-workers successfully isolated (from 60% ethanoic 
extracts) hyacinthacine C1 as well as new Hyacinthacines A1, 
A2, A3 and B3 (See Table 1).[42] When tested against a panel 
of glycosidases, hyacinthacines A1, A2, A3 and B3 displayed 
weak to moderate activity against rat intestinal lactase β-
galactosidase (IC50 values of 4.4 µM, 73 µM, 160 µM and 18 
µM, respectively) and also A. niger amyloglucosidase (IC50 
values of 25 µM, 8.6 µM, 17 µM and 51 µM, respectively). 
Hyacinthacine A1 proved to be the only alkaloid active 
against rat epididymis α-L-fucosidase (IC50 = 46 µM) and 
also rice α-glucosidase (IC50 = 240 µM). Hyacinthacine A1 
and A2 also displayed activity against almond β-glucosidase 
with IC50 values of 250 µM and 150 µM, respectively.[42]  
Despite what could be considered a small compound library, 
Asano and co-workers remarked on the difficulty to predict 
the specificity and potency of glycosidase inhibition, based 
on absolute configuration and also the degree of substitution 
on the pyrrolizidine ring.[42] Concluding statements from 
this body of work highlighted the need for a variety of highly 
oxygenated or substituted pyrrolizidine alkaloids to better 
understand the structural requirements for glycosidase 
inhibtition.[42] Concurrently, glycosidase inhibitors were 
also receiving considerable attention as therapeutic agents. In 
addition to potential treatment for NIDDM (type II diabetes), 
glycosidase inhibitors were also established as possible 
treatments for tumor metastasis, viral infections, and various 
lysosomal storage disorders.[20, 43-47] For these reasons, 
investigation into the hyacinthacine type alkaloids also 
received increased attention and resulted in perhaps the most 
profitable recordings of novel hyacinthacine alkaloids 
isolated from a single species to date by Asano et al. in 
2002.[48] Their report detailed the analysis of the bulbs of 
the related Scilla sibrica that were originally purchased from 
a flower shop in 1999. Specifics of this report include 9 kg 
of S. sibirica bulbs being homogenized in 60% aqueous 
ethanol, and further extracted to give seven new 
hyacinthacine alkaloids appropriately named hyacinthacines 
A4, A5, A6, A7, B4, B5 and B6 (See Table 1).[48] Although the 
majority of these hyacinthacine alkaloids proved relatively 
inactive towards the selected panel of glycosidases, they still 
added to the understanding of the structure-activity 
relationships of these and related compounds. In summary, 
the only active hyacinthacine alkaloids were A5, B4, and B5, 
where they showed inhibitory activity towards the 
amylglucosidase of A. niger with IC50 values of 110 µM, 89 
µM and 110 µM, respectively. In addition to this, 
hyacinthacine B4 displayed a moderate inhibition of bovine 
epididymis α-L-fucodisase with an IC50 value of 23 µM.[48]  
Two years later, Asano and co-workers reported findings of 
long side chain pyrrolidines and pyrrolizidines in a closely 
related Asparagaceae, Scilla peruviana.[49] Asano et al. 
isolated three novel hyacinthacine A1-type related alkaloids 
along with one novel australine type related alkaloid.[49] 
These long-chain hyacinthacine derivatives were isolated 
from 5 kg of the bulbs using 50% aqueous ethanoic extracts 
and were accordingly named α-5-C-(3-
hydroxybutyl)hyacinthacine A1, α-5-C-(1,3-
dihydroxybutyl)hyacinthacine A1, α-5-C-(1,3,4-
trihydroxybutyl)hyacinthacine A1 and α-5-C-(3-
hydroxybutyl)-7-epi-australine (See Table 1).[49] When 
tested against a panel of glycosidases, α-5-C-(1,3-
dihydroxybutyl)hyacinthacine A1 and α-5-C-(3-
hydroxybutyl)-7-epi-australine displayed relatively good 
activity against yeast α-glucosidase (IC50 values of 3.6 µM 
and 6.6 µM, respectively), however only the former alkaloid, 
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along with α-5-C-(1,3,4-trihydroxybutyl)hyacinthacine A1, 
proved relatively low inhibition against almond β-
glucosidase and C. saccharolyticum β-glucosidase with IC50 
values of 9.5 µM, 25.4 µM and 5.1 µM, 11.4 µM, 
respectively.[49] 
The most recent addition to the naturally occurring 
hyacinthacine alkaloids is the 2007 reporting of six new 
isolates from Scilla socialis.[50] Kato and co-workers 
initially purchased plants of S. socialis in 2003 and 
cultivated this species in a heated greenhouse. Once grown, 
2.3 kg of the plant bulbs were homogenized in a 50% ethanol 
solution and further investigated whereby α-5-C-(3-
hydroxybutyl)hyacinthacine A2, Hyacinthacine B7, C2, C3, C4 
and C5 were isolated and tested against a panel of selected 
glycosidases (See Table 1). Of these results, hyacinthacine 
C2, C3 and C5 proved noteworthy activity against C. 
saccharolyticum β-glucosidase with IC50 values of 13 µM, 
25 µM and 48 µM, respectively. Hyacinthacine C4 proved to 
be the only active compound against rice α-glucosidase (IC50 
= 110 µM), but shared similar activities with hyacinthacine 
C5 against rat α-glucosidase (IC50 = 45 µM and 77 µM, 
respectively) and the amyloglucosidase of A.niger (IC50 = 57 
µM for both C4 and C5). Hyacinthacine C3 displayed a 
unique inhibition of bovine liver β-galactosidase with an IC50 
value of 52 µM, whilst hyacinthacine C2 proved the only 
alkaloid capable of inhibiting human placenta α-L-fucosidase 
with an IC50 value of 17 µM.[50] 
 
2.2. Current issues with the hyacinthacine alkaloids 
Excluding the three long-chain hyacinthacine A-type 
analogues, 19 hyacinthacine type alkaloids have been 
isolated and reported between 1999 and 2007. In most cases, 
2D NMR experiments (gCOSY, HSQC, HMBC) were the 
sole basis of structure elucidation. Moreover, NOE 
correlation as well as 3JH,H coupling patterns and constants 
were used to determine the relative configuration but were 
limited such that they were unable to identify the absolute 
configuration of the isolated hyacinthacines. With no X-ray 
crystallographic structures of these complex natural isolates, 
this has understandably led to inconsistencies among the 
hyacinthacines and suggests that their assigned 
configurations are not secure. An immediately obvious 
example of this can be seen in the proposed structures of 
hyacinthacines C1 and C4. Although reported nearly eight 
years apart, both alkaloids were assigned with identical 
structures despite their prominent differences in both 1H and 
13C NMR spectroscopic data and their optical rotations. 
Despite plausible NOE correlations presented for both 
structures (Figure 7), the aforementioned differences 
between the spectroscopic data suggests at least one of these 
structures to be incorrect.[41, 50] 
 
 Figure 7. The NOE correlations reported for hyacinthacine 
C1[41] and C4.[50] 
 
Therefore, to confirm their structures, including the proposed 
relative and absolute configurations, the hyacinthacine 
alkaloids have been of recent interest for total synthesis. 
Furthermore, total synthesis also allows access to the core 
structure of these complex alkaloids and so presents a great 
significance to the large community interested in the 
preparation of glycosidase inhibitors and consequent 
therapeutic iminosugars.  
To date, fourteen of the natural hyacinthacines, A1, A2, A3, 
A6, A7, B1, B2, B3, B4, B5, B7, C2, C3 and C5 have been 
synthesized, along with their related epimers and 
enantiomers.[51-64] At this point, the authors note that an 
increasing number of reports suggest the confirmation of 
hyacinthacine A5 through methods of total synthesis.[61, 63, 
65] To the best of our knowledge, hyacinthacine A5 has not 
yet been synthesized and although epimers of the structure 
have been reported,[66] the absolute configuration of the 
natural isolate is still yet to be confirmed. In addition to the 
aforementioned issues, recent synthetic studies have also 
revealed that the original structures proposed for 
hyacinthacine B7, C3 and C5 are incorrect.[58-62] It therefore 
becomes apparent that structural revision of the original 
isolates is necessary because as demonstrated in the earlier 
table, hyacinthacine alkaloid epimers determine the degree 
of specificity as well as the potency for the inhibition of 
various glycosidases. 
 
2.3. Total syntheses of the hyacinthacine alkaloids 
Each subclass of the hyacinthacine alkaloids displays 
relatively low glycosidase inhibitory activities and so merits 
their total synthesis. Relative to A-type hyacinthacines, both 
B and C-type alkaloids have a greater constitutional 
complexity and as a result, have led to a greater number of 
insecure structural assignments. Synthetic work towards 
hyacinthacine A and B-type alkaloids has been included in a 
number of reviews,[67-69] with a comprehensive analysis 
completed in 2012 by Pyne et al.[70] The hyacinthacine C-
type alkaloids on the other hand have attracted considerable 
interest and there has been a number of publications towards 
their synthetic work that has not yet been summarised. When 
considered from a structural point of view, the hyacinthacine 
C-type alkaloids are the most diverse subclass of the 
hyacinthacines. They contain at least six possible stereogenic 
centres, which means that there is a minimum of 32 unique 
possible diastereomers (plus their enantiomers) that can 
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contain a 3-hydroxymethyl-5-methylpyrrolizidine-1,2,6,7-
tetraol core. Their high degree of oxidation presents a 
remarkably analogous structure to glucose and is therefore 
an enticing, but challenging synthesis for chemists interested 
in accessing medicinally useful iminosugars. For these 
reasons, the remainder of this chapter will largely focus on 
the hyacinthacine C-type alkaloids and will aim to deliver a 
comprehensive and collective review of all the different 
synthetic approaches towards this subclass of hyacinthacine.  
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Table 1: Concentration (µM) of the naturally isolated hyacinthacine alkaloids giving 50% inhibition of various glycosidases 
(IC50 values) 
a “-” : Not tested, bNI : No inhibition (less than 50 % inhibition at 1000 µM) 
 
 
 IC50 (µM) 
    
enzyme Hyacinthacine A1 Hyacinthacine A2 Hyacinthacine A3 Hyacinthacine A4 
α-glucosidase     
 Yeast -a - - NI 
Rice 240 NI NI NI 
Rat intestinal maltase NIb NI NI NI 
 Rat liver lysosome - - - NI 
 
β-glucosidase     
 Almond 250 150 NI - 
 Caldocellum 
saccharolyticum 
- - - 
NI 
 Human Placenta - - - - 
 
α-galactosidase     
 Coffee beans - - - - 
 
β-galactosidase     
 Bovine liver - - - NI 
 Rat intestinal lactase 4.4 73 160 - 
 Rat epididymis - - - - 
 
α-mannosidase     
 Jack bean NI NI NI - 
 Rat epididymis - - - - 
 
β-mannosidase     
 Snail - - - - 
 Rat epididymis 390 1000 NI NI 
 
α-L-fucosidase     
 Bovine epididymis - - - NI 
 Rat epididymis 46 NI NI - 
 Human placenta - - - - 
 
α,α-trehalase     
 Porcine kidney NI 260 NI - 
 
amyloglucosidase     
 Aspergillus niger 25 8.6 17 NI 
 
α-L-rhamnosidase     
 Penicillium 
decumbens 
- - - NI 








 IC50 (µM) 







    
enzyme Hyacinthacine A5 Hyacinthacine A6 Hyacinthacine A7 Hyacinthacine B1 
α-glucosidase     
 Yeast NI NI NI - 
Rice NI NI NI NI 
Rat intestinal maltase NI NI NI NI 
 Rat liver lysosome NI NI NI - 
 
β-glucosidase     
 Almond - - - 320 
 Caldocellum 
saccharolyticum 
NI NI NI 520 
 Human placenta - - - - 
 
α-galactosidase     
 Coffee beans - - - - 
 
β-galactosidase     
 Bovine liver NI NI NI 110 
 Rat intestinal lactase - - - 270 
 Rat epididymis - - - - 
 
α-mannosidase     
 Jack bean - - - - 
 Rat epididymis - - - - 
 
β-mannosidase     
 Snail - - - NI 
 Rat epididymis NI NI NI - 
 
α-L-fucosidase     
 Bovine epididymis NI NI NI NI 
 Rat epididymis - - - - 
 Human placenta - - - - 
 
α,α-trehalase     
 Porcine kidney - - - NI 
 
amyloglucosidase     
 Aspergillus niger 110 NI NI NI 
 
α-L-rhamnosidase     
 Penicillium 
decumbens 
NI NI NI - 
 IC50 (µM) 







   
enzyme Hyacinthacine B2 Hyacinthacine B3 Hyacinthacine B4 Hyacinthacine B5 
α-glucosidase     
 Yeast - - NI NI 
Rice NI NI NI NI 
Rat intestinal maltase NI NI NI NI 
 Rat liver lysosome - - NI NI 
 
β-glucosidase     
 Almond 100 NI - - 
 Caldocellum 
saccharolyticum 
490 - NI NI 
 Human placenta - - - - 
 
α-galactosidase     
 Coffee beans - - - - 
 
β-galactosidase     
 Bovine liver 160 - NI NI 
 Rat intestinal lactase 3.6 18 - - 
 Rat epididymis - - - - 
 
α-mannosidase     
 Jack bean - NI - - 
 Rat epididymis - - - - 
 
β-mannosidase     
 Snail NI - - NI 
 Rat epididymis - NI NI - 
 
α-L-fucosidase     
 Bovine epididymis NI - 23 NI 
 Rat epididymis - 850 - - 
 Human placenta - - - - 
 
α,α-trehalase     
 Porcine kidney NI NI - - 
 
amyloglucosidase     
 Aspergillus niger NI 51 89 110 
 
α-L-rhamnosidase     
 Penicillium decumbens - - NI NI 













α-glucosidase     
 Yeast NI - - - 
Rice NI NI NI NI 
Rat intestinal maltase NI NI NI NI 
 Rat liver lysosome NI - - - 
 
β-glucosidase     
 Almond - - NI - 
 Caldocellum 
saccharolyticum 
NI NI NI 13 
 Human placenta - - - - 
 
α-galactosidase     
 Coffee beans - NI - NI 
 
β-galactosidase     
 Bovine liver NI NI NI 370 
 Rat intestinal lactase - - NI - 
 Rat epididymis - - - - 
 
α-mannosidase     
 Jack bean - NI - NI 
 Rat epidiymis - - - - 
 
β-mannosidase     
 Snail - - NI - 
 Rat epididymis NI - - - 
 
α-L-fucosidase     
 Bovine epididymis NI - NI - 
 Rat epididymis - - - - 
 Human Placenta - NI - 17 
 
α,α-trehalase     
 Porcine kidney - - NI - 
 
amyloglucosidase     
 Aspergillus niger NI 270 84 550 
 
α-L-rhamnosidase     
 Penicillium decumbens NI - - - 











 IC50 (µM) 









α-glucosidase     
 Yeast - - - NI 
Rice NI 110 NI NI 
Rat intestinal maltase NI 45 77 NI 
 Rat liver lysosome - - - - 
 
β-glucosidase     
 Almond - - - 49 
 Caldocellum 
saccharolyticum 
25 660 48 136 
 Human placenta - - - NI 
 
α-galactosidase     
 Coffee beans NI NI NI NI 
 
β-galactosidase     
 Bovine liver 52 890 900 NI 
 Rat intestinal lactase - - - - 
 Rat epididymis - - - NI 
 
α-mannosidase     
 Jack bean NI NI NI - 
 Rat epidiymis - - - NI 
 
β-mannosidase     
 Snail - - - - 
 Rat epididymis - - - NI 
 
α-L-fucosidase     
 Bovine epididymis - - - NI 
 Rat epididymis - - - - 
 Human Placenta NI NI NI - 
 
α,α-trehalase     
 Porcine kidney - - - - 
 
amyloglucosidase     
 Aspergillus niger 870 57 57 - 
 
α-L-rhamnosidase     
 Penicillium decumbens - - - NI 























α-glucosidase     
 Yeast 3.6 650 - 6.6 
Rice 300 390 NI NI 
Rat intestinal maltase 350 NI NI NI 
 Rat liver lysosome - - -  
 
β-glucosidase     
 Almond 9.5 25.4 - NI 
 Caldocellum 
saccharolyticum 
5.1 11.4 NI 200 
 Human placenta NI NI - NI 
 
α-galactosidase     
 Coffee beans NI NI NI NI 
 
β-galactosidase     
 Bovine liver 830 920 NI 320 
 Rat intestinal lactase - - - - 
 Rat epididymis NI NI - NI 
 
α-mannosidase     
 Jack bean - - NI - 
 Rat epididymis 680 NI - NI 
 
β-mannosidase     
 Snail - - - - 
 Rat epididymis NI NI - NI 
 
α-L-fucosidase     
 Bovine epididymis NI NI - NI 
 Rat epididymis - - - - 
 Human Placenta - - NI - 
 
α,α-trehalase     
 Porcine kidney - - - - 
 
amyloglucosidase     
 Aspergillus niger - - 180 - 
 
α-L-rhamnosidase     
 Penicillium decumbens 180 NI - NI 
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2.4. Yoda et al. 2009 
 
The first synthesis of hyacinthacine C-type alkaloids was the 
synthesis of hyacinthacine C2 and C3 along with their C5-
epimers reported by Yoda et al. in 2009.[60] This synthesis 
was an initial attempt to reveal information regarding 
structure-activity relationships between the hyacinthacine C-
type alkaloids and their inhibition against various 
glycosidases. Their synthetic strategy (Scheme 1) starts with 
the preparation of the N-Boc lactam 1 from commercially 
available (S)-(–)-2-pyrrolidone-5-carboxylic acid. The N-Boc 
lactam 1 was subjected to a Grignard addition followed by a 
1,2-reduction of the resulting unsaturated ketone formed by 
pyrrolidinone ring opening to give the corresponding allyl 
alcohol. Subsequent mesylation-cyclization then afforded the 
N-Boc-2 product. Next, the Boc protecting group was 
replaced with Cbz in a high yielding, three step, procedure to 
give N-Cbz-3. The olefin moiety of N-Cbz-3 was then 
subjected to oxidative cleavage with OsO4 and NaIO4 to give 
aldehyde 4 as a single isomer. A Reformatsky-type allylation 
of 4 returned a 79:21 separable mixture of the alcohols 5a 
and 5b, respectively. To establish the methodology, alcohol 
5a then underwent TBS protection of the hydroxy group 
followed by a non-selective dihydroxylation of the terminal 
olefin moiety. The inseparable diol mixture was then 
subjected to a selective TBS protection of the primary 
alcohol, affording a high yield (92%) of a 1:1 mixture of 
separable diastereomers 6a and 6b. In separate reactions, 
mesylation of the secondary alcohols of 6a and 6b followed 
by Cbz deprotection resulted in concerted cyclization to give 
the pyrrolizidines 7a and 7b. Individual global deprotection 
of both pyrrolizidines afforded hyacinthacine C2 along with 
its epimer, 5-epi-hyacinthacine C2 10 in 72% and 71% 
yields, respectively. Having established the synthetic 
pathway to hyacinthacine C2, Yoda and co-workers 
employed a similar synthetic methodology to alcohol 5b 
where they also successfully synthesized hyacinthacine C3 
along with its epimer, 5-epi-hyacinthacine C3 11. When 
compared with the spectroscopic data of the natural 
isolates,[50] Yoda et al. confirmed only the structure for 
natural hyacinthacine C2 was correct. They found that the 
characterization data of their synthetic sample of 
hyacinthacine C3 was inconsistent with the corresponding 
natural product.  
 
2.4. Tamayo et al. 2009 
 
At around the same time as Yoda et al., Tamayo and co-
workers published their work detailing the synthetic 
approach to making analogues of hyacinthacines C2/3 from 
the arabinose derived nitrone 12 (Scheme 2).[71] Their 
synthesis began with the 1,3-dipolar cycloaddition of the 
chemoenzymatically prepared 3-buten-1,2-diol derivatives 
13a or 13b to nitrone 12 to afford cycloadducts 14 or 15, 
respectively. At this stage, methodological probing was 
performed with the pyrroloisoxazolidine 14, which was 
subsequently converted into the mesylate 16. Compound 16 
underwent an N-O reduction with Zn/AcOH, which after a 
basic work up, spontaneously cyclized to give the 
pyrrolizidine 18. Deacetylation to give 19, followed by a 
catalytic hydrogenation under acidic conditions afforded the 
final product 20. After access to the pyrrolizidine core was 
established, Tamayo and co-workers focused their attention 
on cycloadduct 15. More specifically, deacetylation of 15, 
followed by a TBDPS protection of the primary alcohol 
afforded 17 in near quantitative yields. Using similar 
methodology (mesylation, N-O reduction, global 
deprotection), the 5-epimer 24 was obtained. Although they 
were not assessed as potential glycosidase inhibitors, access 
to these highly oxygenated iminosugars is still important for 
the broader community interested in synthesizing complex 
aza-sugars.  
 
2.5. Tamayo et al. 2010 
At this stage, hyacinthacines C1, C4 and C3 proved to be 
insecure in their structural assignment. Their glycosidase 
inhibitory activities proved noteworthy, but difficult to 
predict, especially due to these inconsistencies. For these 
reasons, Tamayo and co-workers were led to investigate and 
report the synthesis of unnatural 7a-epi-hyacinthacine C1 36 
and 5,7a-di-epi-hyacinthacine C1 37 in 2010.[72] From their 
previous work towards the synthesis of hyacinthacine A-type 
alkaloids, [73] Tamayo et al. recognized that using the 
common precursor, the ,-unsaturated ketone 25, would 
afford access to both hyacinthacine C-type alkaloids 
(Scheme 3). More specifically, 25 was subjected to a 
catalytic dihydroxylation using OsO4 and NMO to afford a 
single diol diastereomer 26 in high yield. The high 
diastereoselectivity achieved is a result of the steric 
hindrance created by both the Boc protecting group at the 
amino moiety as well as the benzyl groups at C-4 and C-3. 
Diol 26 was then acetylated in good yield to afford the di-O-
acetylated 27, which was subsequently reduced with NaBH4 
to afford a separable mixture of alcohols 28 and 29 in a 1:1 
ratio (isolated yields of 25% and 22%, respectively). To 
prepare the pyrrolizidine core, alcohols 28 and 29 underwent 
separate mesylation reactions, followed by an acid-catalysed 
N-Boc deprotection to give the secondary amines 32 and 33, 
respectively. After heating at reflux in THF under basic 
conditions, both amines cyclised to give their respective 
pyrrolidine cores. To both pyrrolizidine mixtures was then 
added MeONa in MeOH to facilitate a one-pot debenzoyl- 
and deacetylation to afford triols 34 and 35, respectively. A 
final O-benzyl deprotection of 34 and 35 revealed the desired 
hyacinthacine C-type analogues, 7a-epi-hyacinthacine C1 36 
and 5,7a-di-epi-hyacinthacine C1 37, respectively. Although 
neither were able to resolve the structural discrepancies in 
the literature, access to stereogenic variations of the heavily 
hydroxylated pyrrolizidine core proves important. Their 
therapeutic potential remains unclear as these compounds 
were not assessed for their glycosidase inhibition.  
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Scheme 1. The first total synthesis of hyacinthacine C2 and proposed structure of C3 and their C5 epimers 10 and 11, 
respectively by Yoda et al.[60] 
 




Scheme 2. The total synthesis of unnatural hyacinthacine C2/3 analogues 20 and 24 by Tamayo et al.[71] 
 
2.6. Yu et al. 2011 
 
In the following year, Yu et al. published their findings 
regarding the synthesis of (–)-hyacinthacine C5, 6-epi-(–)-
hyacinthacine C5 and 7-epi-(–)-hyacinthacine C5 from the L-
arabinose derived cyclic nitrone 38 (Scheme 4).[61] This not 
only expanded the number of hyacinthacine C-type 
analogues synthesized, but it was also the first synthesis of 
the enantiomer of natural isolate hyacinthacine C5. Their 
synthesis began with the addition of the lithiated dithiane 39 
to the cyclic nitrone 38 which returned the stereoselective 
hydroxylamine intermediate 40. Compound 40 was then 
subjected to Cope-House cyclization conditions which 
afforded the separable pyrrolizidine N-oxides 41 and 42 in a 
1:1 ratio (55% combined yield). Pyrrolizidine N-oxides 41 
and 42 were then separately reduced using Zn-HOAc to 
afford the pyrrolizidines 43 and 44, respectively. Initially 
focusing on the enantiomer of hyacinthacine C5, the 
dithioketal moiety of pyrrolizidine 43 was hydrolysed to its 
corresponding ketone, which was then selectively reduced to 
the corresponding diol 45 in an overall 31% yield. 
Subsequent debenzylation revealed the final product as (–)-
hyacinthacine C5. Turning their attention to the related 
epimers, Yu and colleagues initially protected the free 
hydroxy moiety in 43 using MOMCl, followed by hydrolysis 
of the dithioketal to give the corresponding ketone in 61% 
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yield. A stereoselective reduction of the ketone with NaBH4 
afforded two separable diastereoisomers favouring the 
desired alcohol 48 in a 5:1 ratio with an overall high yield 
(95.5%). Global deprotection of the MOM and the O-benzyl 
groups afforded (–)-7-epi-hyacinthacine C5 49. Having 
established the synthetic pathway, Yu and co-workers 
successfully synthesized (–)-6-epi-hyacinthacine C5 52 by 
subjecting 44 to similar methodology. With the three 
products in hand, Yu et al. reported that none of the 1H NMR 
and 13C NMR spectroscopic data matched with those 
reported for the natural isolate labelled (+)-hyacinthacine 
C5.[50] This led to the conclusion that natural (+)-
hyacinthacine C5 was in fact, a different isomer. Regardless, 
all synthetic isomers of this study were assayed as potential 
glycosidase inhibitors and found that (–)-6-epi-hyacinthacine 
C5 52 is a weak inhibitor against the α-glucosidases of rat 
intestinal maltase (IC50 = 58.5 µM) and rice (IC50 = 64.2 
µM). 
 
2.7. Tamayo et al. 2011 
 
At the same time as Yu et al. and for similar reasons, 
Tamayo and co-workers also published related work 
detailing a synthetic approach towards (+)-hyacinthacine C5 
along with its C6, C7-diepimer.[62] Their synthesis began 
with the N-Cbz protected pyrrolidine 53, a 2,5-dideoxy-2,5-
imino-D-mannitol (DMDP) derivative (Scheme 5). In this 
synthesis, the primary alcohol of 53 was initially oxidised its 
corresponding aldehyde 54, which was further treated in situ 
with 1-triphenylphosphoranylidene-2-propanone to afford 
the α,β-unsaturated ketone 55. A non-selective 
dihydroxylation of 55 with OsO4 and NMO returned a 1.4:1 
separable mixture of diols 56 and 57, respectively. 
Individually, both diols 56 and 57 were subjected to 
reductive amination to form their respective iminium 
intermediates 58 and 59. Prolonged exposure to catalytic 
hydrogenation conditions over Pd/C resulted in a 
stereospecific hydrogenation occurring anti to the sterically 
encumbering CH2OTBDPS group of both pyrrolizidines. 
More specifically, both pyrrolizidines 60 and 61 were 
synthesized with the same C5-stereochemistry. Individual 
global deprotections of pyrrolizidines 60 and 61, which 
included a desilylation and hydrogenolysis of the benzyl 
protecting groups, revealed both (+)-hyacinthacine C5 and 
(+)-6,7-di-epi-hyacinthacine C5 64, respectively. Arriving to 
a similar conclusion made by Yu et al., Tamayo and 
colleagues also found that neither of their spectroscopic data 
for hyacinthacine C5 and its C6, C7-diepimer 64 matched 
that of the natural isolate[50] further suggesting it to be a 
different isomer. The final products of this study were not 
assessed for their glycosidase inhibitory activities. 
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Scheme 3. The synthesis of unnatural hyacinthacine C1 analogues, 7a-epi-hyacinthacine C1 36 and 5,7a-di-epi-hyacinthacine C1 
37 by Tamayo et al.[72] 
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Scheme 4. A total synthesis of the proposed structure of (–)-hyacinthacine C5, (–)-6-epi-hyacinthacine C5 52 and (–)-7-epi-
hyacinthacine C5 49 by Yu et al.[61] 
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Scheme 5. The total synthesis of the proposed structure of (+)-hyacinthacine C5 and (+)-6,7-di-epi-hyacinthacine C5 64 by 
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2.8. Fischer et al. 2014 
 
By 2014, synthetic work towards the hyacinthacine C-type 
alkaloids had revealed several structural inconsistencies 
among their natural isolates. For this reason, and to also 
expand the scope of information pertaining to these 
compounds, Fischer and co-workers investigated the 
usefulness of asymmetric 1,3-dipolar cycloadditions to 
prepare optically active nitrone templates towards making 
various polyhydroxylated pyrrolizidine analogues.[74] One 
of the iminosugars prepared by Fischer and co-workers can 
be considered an unnatural hyacinthacine C-type alkaloid 
shown in Scheme 6. To obtain this analogue, Fischer et al. 
began their synthesis through the preparation of the 
mannose-derived nitrone 65 (Scheme 6). The cyclic nitrone 
65 underwent a 1,3-dipolar cycloaddition with vinyl acetate 
and afforded a 9:1 isolatable mixture of isoxazolidines, 
favouring the formation of 66 for steric reasons. The acetate 
moiety of 66 then underwent a SN1-like reaction with 
silylketene acetal 67, which exclusively produced the 2,3a-
trans-isoxazolidine 68 in a 69% yield. In a two-step 
procedure, the methyl ester of isoxazolidine 68 was initially 
reduced with LiAlH4, then subsequently protected with tert-
butyl(diphenyl)silyl chloride to give isoxazolidine 69 in 
good yield (84% over two steps). The dimethyoxy ketal 
moiety in compound 69 was then hydrolysed to the ketone to 
give product 70, which was subjected to N-O bond reduction 
and then reductive amination by hydrogenation over Pd/C to 
afford the pyrrolizidine 71 as a single isomer. A global 
deprotection including the removal of the silyl and the 
isopropylidene moieties returned the hexahydroxylated 
pyrrolizidine 73 in 76% yield over two steps.   
 
2.9. Vankar et al. 2014 
 
In the same year, Vankar and co-workers reported their 
synthetic work towards the synthesis of homoanologues of 
hyacinthacine C5.[75] Their 2014 report details starting from 
the arabinose-based cyclic nitrone 74 which underwent a 1,3-
dipolar cycloaddition reaction with the D-mannitol-aldehyde 
derived dipolarphile 75 (Scheme 7). The desired cycloadduct 
76 was obtained in a 9:1 ratio in a combined yield of 88%. 
Compound 76 was then subjected to a Zn/HOAc mediated 
N-O cleavage which produced the pyrrolidine 77 which then 
underwent selective benzylation at the secondary amine to 
give 78 in 85% over two steps. The ester moiety of 78 was 
then reduced to its corresponding alcohol to afford diol 79. A 
non-selective O-benzylation of both hydroxy groups 
afforded 80, which upon removal of the cyclohexylidene 
acetal, resulted in the formation of the diol 81. The diol 
moiety of compound 81 was then oxidatively cleaved with 
sodium periodate to give aldehyde 82 which was then treated 
with MeMgI, returning a selective 10:1.2 mixture of 
diastereomers 83a and 83b. The diastereomeric mixture was 
then oxidised to the respective ketone product 84, which 
after a reductive amination followed by a benzyl ether 
deprotection, afforded the crude hyacinthacine C-type 
analogue 86. To purify 86, Vankar et al. peracetylated the 
crude mixture, followed by its deprotection. After washing 
the residue with chloroform, the purified 86 was obtained.   
 
Short Running Title of the Article Journal Name, 2019, Vol. 0, No. 0    23 
 
 
Scheme 6. A total synthesis of an unnatural hyacinthacine C2/3 analogue 73 by Fischer et al.[74] 
 
 
Scheme 7. A total synthesis of the hyacinthacine C-type related analogue 86 by Vankar et al.[75] 
2.10. Vankar et al. 2016 
In continuation with synthetic efforts towards synthesizing 
different unnatural analogues of bicyclic iminosugars, 
Vankar et al. reported in 2016, a new strategy for accessing a 
large number of complex hyacinthacine C2/3 related 
products.[76] Vankar and co-workers’ synthesis of the 
unnatural hyacinthacine C-type alkaloids can be summarised 
in Scheme 8. Their synthetic work began with the oxidation 
of pyrrolidine 87 to its corresponding aldehyde using a CrO3-
pyridine-Ac2O reagent system. The aldehyde formed was 
then treated with allylzinc bromide to afford compound 88 
which underwent O-benzylation to the product 89. The 
olefin moiety of compound 89 was then subjected to a 
nonselective dihydroxylation with OsO4 and NMO which 
returned an inseparable mixture of diols. A selective 
protection of the primary alcohol in each diol resulted in the 
corresponding silyl ethers 90 and 91, which were readily 
separable. To establish the methodology, Vankar and co-
workers quantitatively mesylated the free hydroxy group in 
compound 90. Without purification, the mesylated 90 then 
underwent a N-Boc deprotection to the corresponding amine 
salt, which under basic conditions furnished pyrrolizidine 92. 
A global deprotection, followed by peracetylation as a means 
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of purification afforded the pentaacetylate 94. After a 
comprehensive structural analysis, the pentaacetylate 94 was 
deprotected using aqueous ammonia in methanol which gave 
the final pentahydroxlyated hyacinthacine C2/3-type analogue 
96. Having established this synthetic route, Vankar and co-
workers then employed a similar reaction scheme to 
diastereomer 91 which successfully converted into 
compound 97. Vankar et al. also readily obtained two more 
epimers, 107 and 108, from subjecting pyrrolidine 98 to the 
same sequence of reactions. The only notable difference is 
that the hydroxy group of olefin 99 was protected as the 
acetate 100 instead of the benzyl ether. Of the four 
hyacinthacine C2/3 products synthesized, none matched the 
putative structure for hyacinthacine C3, but they certainly 
provided a better understanding towards the access to these 
complex iminosugars. Additionally, the biological activities 
the final products were evaluated as potential glycosidase 
inhibitors against a panel of eight commercially available 
enzymes. The hyacinthacine analogues 96 and 107 displayed 
selective activity against jack bean α-mannosidae (IC50 = 
81.2 µM and IC50 = 95 µM, respectively) with analogue 107 
also displaying moderate activity against coffee bean α-
galactosidase (IC50 = 120 µM). Final remarks from the 
authors suggested that given these activities, hyacinthacine 
analogues 96 and 107 are potential anti-diabetic and anti-
cancer leads, respectively.  
2.11. Goti et al. 2017 
A recent addition towards the synthesis of the hyacinthacine 
C-type alkaloids was reported in 2017 by Goti and co-
workers through their synthesis of the proposed structure of 
(+)-hyacinthacine C5 and its C-5 epimer 120.[63] Their goal 
was to implement a straightforward and convenient synthesis 
towards these complex iminosugar motifs. To access both 
these structures, their convergent synthesis began with the 
preparation of both the arabinose-derived cyclic nitrone 109 
and the racemic lithiated 3-methyl-substituted 
benzyloxyallene 110 (Scheme 9). The lithiated derivative 
110 was then added to nitrone 109 to form intermediate 111, 
which upon standing at room temperature for 24 hours, 
cyclized to afford a 1:1 separable mixture of 1,2-oxazines 
112 and 113. Both oxazines were then individually subjected 
to hydroboration which delivered respective alcohols 114 
and 115. Goti and co-workers were initially focused on 
establishing the synthetic pathway towards the proposed 
structure of (+)-hyacinthacine C5 and so their attention 
turned to alcohol 114 which was protected to give the penta-
benzylated product 116. Next, a reductive amination of 116 
with samarium diiodide in THF cleaved the N-O bond to 
give the amino-alcohol, which was subsequently converted 
to pyrrolizidine 118 via mesylation of the primary hydroxy 
group, then spontaneous cyclization. Finally, all benzyl ether 
groups were removed via hydrogenolysis to afford the 
purported (+)-hyacinthacine C5. Using a similar method, 5-
epi-hyacinthacine C5 120 was synthesized after alcohol 115 
underwent a reductive amination followed by bis-mesylation 
of the hydroxy groups which concurrently cyclized to give 
pyrrolizidine 119. After a LiAlH4 reduction of the sulfonyl 
group on 119, the corresponding alcohol was subjected to 
hydrogenolysis to give the globally deprotected 
pyrrolizidine, 5-epi-hyacinthacine C5 120.  
As per the previous reports by Yu et al.[61] and Tamayo et 
al.,[62] Goti and co-workers also found that the 
configuration of the putative structure of hyacinthacine C5 
was incorrect. Neither structure synthesized in this report 
matched the spectroscopic data of the natural isolate. Despite 
being unable to resolve the true structure of hyacinthacine 
C5, Goti et al. revised the originally reported NOE 
enhancements for the natural isolate and after finding similar 
NOE correlations in their synthetic products, were able to 
suggest an alternative configuration which could be 
appropriately labelled as 1-epi-hyacinthacine C4 (Figure 8). 
 
Figure 8. The NOE signals reported for the putative 
hyacinthacine C5 (left) along with the revised NOE signals 
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Scheme 8. A stereodivergent synthesis of hyacinthacine C2/3 related analogues 96, 107, 97 and 108 by Vankar et al.[76] 
 
 








2.12. Pyne et al. 2018 
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Pyne and co-workers employed a flexible synthesis which is 
the latest addition towards accessing the hyacinthacine C-
type alkaloids.[64] This synthetic work resulted in a total of 
seven hyacinthacine C-type analogues including the total 
synthesis of natural (+)-hyacinthacine C5 141 and confirmed 
the hypothesis proposed by Goti et al. that its true 
configuration is that of (+)-1-epi-hyacinthacine C4. In this 
synthesis, Pyne et al. used a key Petasis borono Mannich 
reaction at one stage to obtain the L-xylose derived anti-1,2-
amino alcohol 121 (Scheme 10). After protecting the 
secondary amine with di-tert-butyl decarbonate to afford 
122, the product was then converted to the oxazolidinone 
123. Compound 123 was then subjected to ring closing 
metathesis (RCM) reaction conditions which afforded the 
bicyclic alkene 124 in 85% yield. The olefin moiety of 
compound 124 was then subjected to a dihydroxylation 
reaction with K2OsO4·H2O and NMO which afforded a 3:1 
mixture of diastereomers 125a and 125b, respectively which 
only separated efficiently after conversion to their acetonides 
126 and 127, respectively. To establish the methodology, 
acetonide 126 was hydrolysed with base under microwave 
conditions to afford amino diol 128, which was subsequently 
converted to the pyrrolizidine 129 in high yield after 
employing Appel cyclization conditions.[77] A global 
deprotection of pyrrolizidine 129 over PdCl2 followed by 
basic-ion exchange chromatography resulted in the (+)-5,6-
di-epi-hyacinthacine C5 130. Using similar methodology, 
hyacinthacine C-type analogue (‒)-5,7-di-epi-hyacinthacine 
C5 133 was also obtained except that its related pyrrolizidine 
core 132 was formed via selective O-mesylation, then heat 
induced cyclization.  
Attention was then focused on manipulating the 
stereoconfiguration of the C6, C7 hydroxy groups without 
affecting the stereochemistry of the A-ring in the 
pyrrolizidine core (Scheme 10). To explore this chemistry, 
the C8 hydroxy group in pyrrolizidine 129 was O-benzylated 
and then acid hydrolysed which returned diol 135. Diol 135 
was then converted to its cyclic sulfate 136 followed by a 
subsequent ring opening with CsOBz (prepared in situ from 
Cs2CO3 and BzOH) which gave an inseparable 1:4 mixture 
of regioisomers 137a and 137b, respectively. The mixture 
was subjected to base mediated hydrolysis of the benzoate in 
137a and 137b which returned isolatable diols 140 and 138, 
respectively. Diols 138 and 140 were individually 
debenzylated under hydrogenolysis conditions (over PdCl2), 
which returned pure samples of both (+)-5-epi-hyacinthacine 
C5 139 and (+)-1-epi-hyacinthacine C4 141, respectively. 
Having obtained four hyacinthacine C-type alkaloids, Pyne 
et al. then applied the same sequence of reactions and 
conditions to a 1:2 mixture of the amino diols 121 and 142, 
respectively (Scheme 11). From the 1´S-142, they secured 
the putative structure of (+)-hyacinthacine C5, along with 
(‒)-7-epi-hyacinthacine C5 149 and (+)-6,7-di-epi-
hyacinthacine C5 158. The spectroscopic data of all final 
products were compared against the spectroscopic data of the 
natural hyacinthacine C1, C4 and C5 alkaloids. It was 
discovered that (+)-1-epi- hyacinthacine C4 141 matched 
both 1H NMR and 13C NMR spectroscopic data and had 
similar specific optical rotations when compared with the 
natural isolate labelled hyacinthacine C5. The authors found 
that their spectroscopic data for synthetic (+)-hyacinthacine 
C5,[61-63] (‒)-7-epi-hyacinthacine C5[61] 149 and (+)-6,7-
di-epi-hyacinthacine C5[62] 158 confirmed the proposed 
structures and absolute configurations of the literature 
reported synthetic products (+)-hyacinthacine C5, (–)-7-epi-
hyacinthacine C5 49 and (+)-6,7-di-epi-hyacinthacine C5 64, 
respectively. However, when they compared their synthetic 
(+)-5-epi-hyacinthacine C5 139 against the same compound 
120 reported by Goti et al., Pyne and co-workers found 
several spectroscopic differences that led them to conclude 
that they were not the same product. To try and resolve this 
issue, they extensively characterised the peraccetylated 
derivative of (+)-5-epi-hyacinthacine C5 139 as well as its 
HCl salt, although neither were a spectroscopic match to the 
product proposed by Goti et al. Pyne acknowledged the 
possibility of a double inversion of amino diols 128, 131 or 
147 after O-mesylation, and so would retain stereochemistry 
in the corresponding pyrrolizidine structures. Given their 
structures for synthetic (+)-hyacinthacine C5, 149 and 158 
were consistent with the previously reported structures for 
(+)-hyacinthacine C5[61], (–)-7-epi-hyacinthacine C5[61] 49 
and (+)-6,7-di-epi-hyacinthacine C5[62] 64, they were 
confident this did not occur. In contrast, Goti and co-workers 
successfully synthesised the proposed structure of 
hyacinthacine C5 but did not employ the same conditions to 
obtain its C5 epimer. Instead they cyclized the bis-mesylated 
amino product 117 and so there is the possibility that 
cyclization could afford the stable 4-membered bicyclic N-
heterocycle.[78] This issue has not yet been resolved and so 
highlights the difficulty often associated with assigning the 
structures of the hyacinthacine C-type alkaloids. Further 
investigation is certainly required.  
Despite this, Pyne and co-workers evaluated the final 
products as potential glycosidase inhibitors. They found that 
130 and 133 showed weak inhibition of the α-glucosidase of 
rat intestinal isomaltase (IC50 values of 20 µM and 42 µM, 
respectively) and moderate inhibition against the α-
glucosidase of rat intestinal sucrase (IC50 values of 13 µM 
and 9.9 µM, respectively). Compound 130 proved to be a 
weak inhibitor against yeast α-glucosidase (IC50 value of 83 
µM) and rat intestinal maltase (IC50 value of 61 µM) but 
showed moderate activity against amylglucosidases from A. 
niger and Rhizopus sp (IC50 values of 25 µM and 16 µM, 
respectively). Compound 149 seemed relatively inactive but 
compound 139 displayed moderate inhibition against α-
glucosidases of rat intestinal maltase and human lysosome 
(IC50 values of 21 µM and 15 µM, respectively) and weak 
inhibition against the amylglucosidase of A. niger (IC50 value 
of 41 µM). Besides 139, only the putative (+)-hyacinthacine 
C5 was noted to display a weak inhibition against the α-L-
rhamnosidase of Penicillium decumbens (IC50 value of 74 
µM). Pyne and co-workers noted a correlation between the 
orientation of the C5 methyl group and the IC50 against each 
enzyme tested. More specifically, if the hyacinthacine C-type 
alkaloid contained an (5S)-methyl then the IC50 values 
increased with consequently a reduction in the selectivity 
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and potency of the compound as a glycosidase inhibitor. 
Comparatively, for a decrease in the IC50, the hyacinthacine 
C-type alkaloids containing an (5R)-methyl proved more 
suitable candidates as potential glycosidase inhibitors. 
 
 
Scheme 10. The total synthesis of (+)-5,6-di-epi-hyacinthacine C5 130, (‒)-5,7-di-epi-hyacinthacine C5 133, (+)-5-epi-
hyacinthacine C5 139 and (+)-1-epi-hyacinthacine C4 141.[64]  
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Scheme 11. The total synthesis of (‒)-7-epi-hyacinthacine C5 149, (+)-hyacinthacine C5, (+)-6,7-di-epi-hyacinthacine C5 
158.[64] 





Research towards pyrrolizidine alkaloid isolation and 
synthesis is of paramount importance. From an economic 
point of view, characterisation of these compounds is 
essential to prevent illness occurring in livestock and more 
importantly, humans. The polyhydroxylated pyrrolizidine 
alkaloids containing a C-3 methyl or hydroxymethyl 
represent only a slight fraction of the ever-growing number 
of discovered pyrrolizidine alkaloids but are of great 
importance as they are potentially medicinally useful. Of 
these, the hyacinthacine C-type alkaloids have generated 
recent interest which can be attributed to their inherent 
glycosidase inhibitory activities, making this class of 
compound suitable candidates for anti-diabetic, anti-obesity, 
anti-cancer and in some cases, anti-bacterial drug scaffolds. 
Their high degree of oxidation in conjunction with complex 
stereochemistry presents as a rewarding synthetic feat for 
any laboratory prepared to undertake their synthesis and is 
beginning to rapidly grow as a research area. Additionally, a 
number of mistakes associated with their structures warrants 
their synthesis as a way to confirm or correct their proposed 
structures. To date, methods of total synthesis have 
confirmed the structure of hyacinthacine C2 to be correct but 
has found that the structure for hyacinthacine C3 requires 
revision. The structures for hyacinthacine C1 and 
hyacinthacine C4 remain insecure since they both contain 
different spectroscopic data but have been assigned the same 
relative stereochemistry. Pyne et al. recently confirmed the 
hypothesis by Goti and co-workers, by synthesizing the 
correct structure for hyacinthacine C5 found to be (+)-1-epi-
hyacinthacine C4. However, their spectroscopic data for (+)-
5-epi-hyacinthacine C5 139 when compared against the same 
compound 120 reported by Goti et al., did not match and so 
requires further investigation. Despite these issues, the 
studies reported in this review have resulted in the synthesis 
of important regio- and stereo-isomers of the hyacinthacine 
C-type compounds and so presents as a great significance to 
the large community interested in the preparation of 
glycosidase inhibiting and consequent therapeutic 
iminosugars. Unfortunately, the glycosidase activities of a 
number of these analogues remains uncertain as they were 
not evaluated for their biological activity. This observation 
suggests the need for an accessible approach for assaying 
these compounds as potential drug motifs for the 
aforementioned illnesses and complications. Although they 
may not ever be marketable drugs, synthetic access and 
glycosidase testing of the hyacinthacine C-type alkaloids 
represent a positive step towards understanding the structure-
activity-relationship of a glycosidase active site mechanisms. 
This foundation prepares the knowledge base required to 
eventually design marketable drugs that manage and 
selectively treat the aforementioned illnesses with minimal 
side effects. 
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